ArticleImmunogenetics2011
Frequent loss of heterozygosity in the β2-microglobulin region of chromosome 15 in primary human tumors.
Article in Immunogenetics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.
- Prognostic and Clinical Significance of Human Leukocyte Antigen Class I Expression in Breast Cancer: A Meta-Analysis.Molecular diagnosis & therapy · 2023Pooled it
- The membrane-associated ubiquitin ligase MARCHF8 degrades MHC-I in HPV-positive head and neck cancer for immune evasion.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Intravesical interferon-α2b gene therapy with nadofaragene firadenovec-vncg: a contemporary review.Future oncology (London, England) · 2025Review
- Review
- Mechanism of action of nadofaragene firadenovec-vncg.Frontiers in oncology · 2024Review
- Immune Evasion Through Human Leukocyte Antigen Implications and Its Impact on Targeted Therapy.Cureus · 2024Review
- Assessment of Impact of Human Leukocyte Antigen-Type and Cytokine-Type Responses on Outcomes after Targeted Therapy Currently Used to Treat Chronic Lymphocytic Leukemia.Journal of clinical medicine · 2023Review
- Article
- Article
- Multiplexed In Situ Spatial Protein Profiling in the Pursuit of Precision Immuno-Oncology for Patients with Breast Cancer.Cancers · 2022Review
- Synergy of a STING agonist and an IL-2 superkine in cancer immunotherapy against MHC I-deficient and MHC IProceedings of the National Academy of Sciences of the United States of America · 2022Article
- The immune-related role of beta-2-microglobulin in melanoma.Frontiers in oncology · 2022Review
- Molecular characterization of type I IFN-induced cytotoxicity in bladder cancer cells reveals biomarkers of resistance.Molecular therapy oncolytics · 2021Article
- HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy.Trends in cancer · 2021Review
- Article
- Deregulation of HLA-I in cancer and its central importance for immunotherapy.Journal for immunotherapy of cancer · 2021Review
- MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It.International journal of molecular sciences · 2021Review
- Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation.The Journal of clinical investigation · 2021Article
- Targeting loss of heterozygosity for cancer-specific immunotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy.Cellular & molecular immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Downregulation or total loss of HLA class I expression on tumor cells is known as a mechanism of cancer immune escape. Alterations of the HLA phenotype are frequently due to mutations affecting genes encoding the HLA class I heavy chains located on chromosome 6p21 or the β2-microglobulin (β2m) gene encoding the light chain of the HLA complex located on chromosome 15q21. Frequently irreversible total loss of HLA class I molecules is due to the coincidence of two molecular events, the mutation of one β2m gene and the loss of the second copy. The latter is detectable as loss of heterozygosity (LOH) of microsatellite markers in the β2m region on chromosome 15q21 (LOH-15q21). Thus, LOH-15q21 might be an important event in the processes of HLA class I downregulation and total loss. Here we studied the frequency of LOH-15q21 in tumor tissues of different entities. By determining the status of heterozygosity of two microsatellite markers we detected LOH-15q21 in 44% of bladder carcinomas (n = 69), in 35% of colon carcinomas (n = 95), in 16% of melanomas (n = 70) but only in 7% of renal cancers (n = 45). Moreover, we observed a frequent coincidence of LOH-15q21 and LOH-6p21 in colorectal carcinoma, bladder carcinoma and melanoma, but not for renal carcinoma. We believe that the high incidence of LOH-15q21 in some malignancies and especially the coincidence of LOH-15q21 and LOH-6p21 might have a strong impact on tumor immunogenicity and on the efficiency of cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.